1. Home
  2. TNFA vs YHC Comparison

TNFA vs YHC Comparison

Compare TNFA & YHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNFA
  • YHC
  • Stock Information
  • Founded
  • TNFA 2014
  • YHC 2021
  • Country
  • TNFA United States
  • YHC United States
  • Employees
  • TNFA N/A
  • YHC N/A
  • Industry
  • TNFA
  • YHC Beverages (Production/Distribution)
  • Sector
  • TNFA
  • YHC Consumer Staples
  • Exchange
  • TNFA NYSE
  • YHC Nasdaq
  • Market Cap
  • TNFA 1.6M
  • YHC 1.4M
  • IPO Year
  • TNFA N/A
  • YHC N/A
  • Fundamental
  • Price
  • TNFA $0.10
  • YHC $4.48
  • Analyst Decision
  • TNFA
  • YHC
  • Analyst Count
  • TNFA 0
  • YHC 0
  • Target Price
  • TNFA N/A
  • YHC N/A
  • AVG Volume (30 Days)
  • TNFA 4.6M
  • YHC 2.7M
  • Earning Date
  • TNFA 08-18-2025
  • YHC 08-13-2025
  • Dividend Yield
  • TNFA N/A
  • YHC N/A
  • EPS Growth
  • TNFA N/A
  • YHC N/A
  • EPS
  • TNFA N/A
  • YHC N/A
  • Revenue
  • TNFA N/A
  • YHC $2,449,906.00
  • Revenue This Year
  • TNFA N/A
  • YHC $69.97
  • Revenue Next Year
  • TNFA N/A
  • YHC $403.29
  • P/E Ratio
  • TNFA N/A
  • YHC N/A
  • Revenue Growth
  • TNFA N/A
  • YHC 68.83
  • 52 Week Low
  • TNFA $0.10
  • YHC $1.13
  • 52 Week High
  • TNFA $2.16
  • YHC $98.00
  • Technical
  • Relative Strength Index (RSI)
  • TNFA 30.72
  • YHC N/A
  • Support Level
  • TNFA $0.11
  • YHC N/A
  • Resistance Level
  • TNFA $0.14
  • YHC N/A
  • Average True Range (ATR)
  • TNFA 0.02
  • YHC 0.00
  • MACD
  • TNFA 0.00
  • YHC 0.00
  • Stochastic Oscillator
  • TNFA 3.64
  • YHC 0.00

About TNFA TNF PHARMACEUTICALS INC EFFEC

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine.

About YHC LQR House Inc. Common Stock

LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.

Share on Social Networks: